Opdivo meets OS endpoint in esophageal cancer trial

Ono Pharmaceutical Co. Ltd. (Tokyo:4528) said anti-PD-1 mAb Opdivo nivolumab met the primary endpoint vs. chemotherapy of improving overall survival in the Phase III ATTRACTION-3 trial to treat esophageal cancer.

Ono said Opdivo is the first checkpoint inhibitor to significantly extend OS in patients with PD-L1 unselected, unresectable advanced or recurrent esophageal cancer. The company, which did not report detailed data, plans to present additional data at a scientific meeting...